MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/220/0.1/20.12.24 | Real-time Bid/Ask 15:55:31 01/07/2024 BST | ||
| 0.099 EUR / 0.105 EUR | +4.08% |
|
| Current month | +44.12% | ||
| 1 month | +66.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 01/07/24 | 0.091 | -7.14% |
| 28/06/24 | 0.098 | -7.55% |
| 27/06/24 | 0.106 | +1.92% |
| 26/06/24 | 0.104 | -17.46% |
| 25/06/24 | 0.126 | +41.57% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 10:04 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME0XDV |
| ISIN | DE000ME0XDV1 |
| Date issued | 21/09/2023 |
| Strike | 220 $ |
| Maturity | 20/12/2024 (172 Days) |
| Parity | 10 : 1 |
| Emission price | 1.9 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.27 € |
|---|---|
| Lowest since issue | 0.035 € |
| Spread | 0.006 € |
| Spread % | 5.77% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Warrants
- Warrant
